| Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response | 06/03 09:30 | prnewswire.com |
| Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting | 05/23 17:00 | prnewswire.com |
| Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates | 05/14 18:20 | zacks.com |
| Precigen Reports First Quarter 2024 Financial Results and Business Updates | 05/14 16:05 | prnewswire.com |
| Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting | 05/08 16:05 | prnewswire.com |
| Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting | 04/24 10:20 | prnewswire.com |
| Actym Therapeutics Appoints Thomas Smart as CEO | 04/24 09:00 | prnewswire.com |
| Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th | 03/28 16:05 | prnewswire.com |
| Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript | 03/19 20:49 | seekingalpha.com |
| Precigen Reports Full Year 2023 Financial Results and Business Updates | 03/19 16:05 | prnewswire.com |